ACVBP

None

Phase II liver, pancreatic, Phase III MM, prostate Doxorubicin hydrochloride encapsulated in liposomes formulated with methoxypolyethylene glycol (MPEG). FDA approved use on bladder cancer, breast cancer, gastric cancer, leukemia, small cell lung cancer, lymphoma, neuroblastoma, ovarian cancer, sarcoma, thyroid cancer, Wilm's tumor. ALZA Corp, NeoPharm, Pharmacia, Schering-Plough, Sequus. Antitumor antibiotic

This drug should be coded

None

Code Prednisone when it is part of a drug regimen.

Do not code Prednisone when it is given to treat symptoms or as a single agent. In most cases when Prednisone is given by itself and not as part of a drug regimen, it does not affect the cancer and would not be coded as treatment.

Please see remarks for additional information

None

An effective antineoplastic agent and is used for a variety of cancers. FDA approved uses on breast cancer, ovarian carcinoma, leukemia, lymphomas, multiple myeloma, neuroblastma, retinoblastoma, soft tissue sarcoma, Wilm's tumor. Alkylating agent

This drug should be coded

None

FDA approved uses on squamous cell cervical cancer, head & neck cancer, Hodgkin's and non-Hodgkin's lymphoma, nasopharyngeal cancer, carcinoma, and testicular cancer.

This drug should be coded

None

None

Vindesine has activity in a wide variety of malignancies including colorectal, lung, breast, and esophageal carcinomas; it also has activity in lymphomas and leukemias, glioma, and melanoma. Neurotoxicity (dose-limiting and cumulative) and cross-resistance with vincristine have limited the usefulness of this agent. Although vindesine in combination with cisplatin is one of the most active regimens for non-small cell lung cancer.

This drug should be coded